ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimers disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Compnies product candidates are PMN310, PMN267, and PMN442. Lead product candidate is PMN310, a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 is companies second lead product candidate targeting ALS.
Last trade$3.25
Day change-$0.06 (-1.81%)
Day range$3.11 – $3.58
Volume93,928
Market cap$30M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$29.68M
Price / earnings
—
Price / book
0.71×
Price / sales
—
EV / sales
—
EV / EBITDA
0.36×
Profitability
Earnings per share
-$4.33
Return on assets
-82.29%
Return on equity
-92.93%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
8.83×
Quick ratio
8.83×
Cash ratio
8.25×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$41.43M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for PMN, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$1.91M
$2.74M
$1.67M
$1.4M
$1.95M
$1.43M
$2M
$1.68M
Research and development
$6.71M
$9.52M
$6.97M
$9.37M
$9.8M
$8.75M
$5.46M
$4.32M
Total operating expenses
$8.62M
$12.27M
$8.64M
$10.77M
$11.75M
$10.18M
$7.46M
$6M
Operating income
-$8.62M
-$12.27M
-$8.64M
-$10.77M
-$11.75M
-$10.18M
-$7.46M
-$6M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$8.16M
-$11.73M
-$8.24M
-$10.67M
-$11.58M
-$10.12M
-$7.35M
-$238.21K
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$8.16M
-$11.73M
-$8.24M
-$10.67M
-$11.58M
-$10.12M
-$7.35M
-$238.21K
Net income attributable to common shareholders
-$8.16M
-$11.73M
-$8.24M
-$10.67M
-$11.58M
-$10.12M
-$7.35M
-$238.21K
EBITDA
-$8.62M
-$12.27M
-$8.64M
-$10.77M
-$11.75M
-$10.18M
-$7.46M
-$6M
Basic earnings per share
-$0.89
-$1.28
-$1.26
-$4.67
-$5.93
-$7.26
-$5.27
-$0.17
Diluted earnings per share
-$0.89
-$1.28
-$1.26
-$4.67
-$5.93
-$7.26
-$5.27
-$0.16
Recent news
Company coverage with links to the original publishers.
ProMIS Neurosciences has licensed TXP1, a brain-selective shuttling technology from Ossianix that demonstrated 65-fold increased antibody delivery to the brain in preclinical studies. The technology will be applied to PMN310 (Alzheimer's disease lead candidate) and optionally to the company's Parkinson's disease and ALS programs. The PRECISE-AD Phase 1b trial remains on track for Q1 2027 topline data.
ProMIS Neurosciences Inc. announced its participation in multiple healthcare conferences throughout November 2026, including presentations and fireside chats by CEO Neil Warma at venues in Boston, New York, and London. The company will present interim safety and biomarker analysis data from its PRECISE-AD trial at the Clinical Trials on Alzheimer's Disease conference.
Over 200 companies are advancing more than 240 pipeline Alzheimer's disease therapies across various clinical development stages. The market is being driven by an aging population, rising disease prevalence, and the emergence of disease-modifying therapies that enable earlier intervention and biomarker-guided care. Two therapies have recently received FDA approval: KISUNLA (donanemab) from Eli Lilly and LEQEMBI (lecanemab-irmb) from Eisai/Biogen, both targeting amyloid plaques to slow disease progression.
ProMIS Neurosciences announced positive interim results from its Phase 1b PRECISE-AD trial of PMN310, an experimental Alzheimer's disease treatment. The drug showed a favorable safety profile with no ARIA-E cases across all genotypes including high-risk APOE4 carriers, and demonstrated early biomarker movement consistent with target engagement. Full 12-month topline results are expected in Q1 2027.
ProMIS Neurosciences announced positive Phase 1a trial results showing PMN310, its lead Alzheimer's drug candidate, achieved dose-dependent reduction of amyloid-beta oligomers in human cerebrospinal fluid. The company demonstrated target engagement in healthy volunteers and plans to present six-month blinded interim data from its Phase 1b PRECISE-AD trial in the coming weeks, with top-line results expected in early Q1 2027.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.